NCT05053854View on ClinicalTrials.gov

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Talazoparib

During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks

Trial Locations (1)

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER